|1.||Beijnen, Jos H: 7 articles (10/2011 - 09/2002)|
|2.||Schellens, Jan H M: 7 articles (10/2011 - 09/2002)|
|3.||Supuran, Claudiu T: 4 articles (08/2012 - 11/2002)|
|4.||Huitema, Alwin D R: 4 articles (10/2011 - 06/2005)|
|5.||Fumoleau, P: 4 articles (01/2005 - 09/2001)|
|6.||Ravic, M: 4 articles (01/2005 - 09/2001)|
|7.||Owa, Takashi: 3 articles (05/2012 - 01/2004)|
|8.||Wanders, Jantien: 3 articles (10/2011 - 11/2003)|
|9.||Dittrich, Christian: 3 articles (10/2007 - 11/2003)|
|10.||Yule, S Murray: 3 articles (03/2007 - 06/2005)|
11/01/2003 - "Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors."
11/01/2002 - "As of January 2001, indisulam was in phase II trials in Europe for the treatment of solid tumors, and phase II US studies have been ongoing since March 2001 . "
09/01/2002 - "The objective of this study was to quantify the excretion of E7070 and the metabolite 1,4-benzene-sulfonamide (M1) in cancer patients. "
09/01/2002 - "An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients."
08/15/2002 - "Prolonged disease stabilization observed in this study might warrant further investigation of E7070 in selected tumor types."
|2.||Melanoma (Melanoma, Malignant)
10/01/2007 - "The objective of this study is to report on long-term survival of a patient with metastatic melanoma treated with indisulam showing a distinct genetic pattern of repression of subsets of genes involved in mitochondrial energy metabolism. "
01/01/2005 - "In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. "
01/01/2005 - "Phase II study of E7070 in patients with metastatic melanoma."
01/01/2005 - "E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma."
10/01/2007 - "Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070)."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/15/2007 - "A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer."
01/01/2001 - "Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells."
03/15/2007 - "We conclude that, despite evidence of tumor-specific indisulam-induced apoptosis, neither of these treatment schedules has single-agent activity as second-line treatment of non-small cell lung cancer."
01/01/2001 - "To elucidate the mechanisms by which E7070 inhibits tumor cell growth, we established and characterized an E7070-resistant subline, A549/ER, from a human non-small cell lung cancer cell line A549. "
02/26/2007 - "The recommended dose and schedule for an envisaged phase II study in patients with non-small cell lung cancer is indisulam 500 mg m(-2) in combination with carboplatin 6 mg min ml(-1) repeated four-weekly. "
10/01/2011 - "For indisulam predictions were better when based on data from the specific study, however when the model parameters were conditioned on data from trials performed prior to a specific study, similar predictions of the drug related-neutropenia profiles and descriptors were obtained as when all data were used. "
06/01/2005 - "A semi-physiological model was successfully applied to describe the time course and extent of the neutropenia and thrombocytopenia after indisulam administration for four treatment schedules."
09/01/2001 - "At E7070 doses of 200 and 160 mg/m2/day dose-limiting toxicities occurred, which consisted of febrile neutropenia, thrombocytopenia. "
10/01/2011 - "Pharmacokinetic and neutropenia data from 5 clinical trials for diflomotecan and from 4 clinical trials for indisulam were used. "
|5.||Lung Neoplasms (Lung Cancer)
01/01/2001 - "Taken together, these results suggest that E7070 exerts its antitumor effects by disturbing the cell cycle at multiple points, including both the G1/S and the G2/M transition, in human lung cancer cells."
11/01/2001 - "Animal tests using human tumour xenograft models demonstrated that E7070 could cause not only tumour growth suppression, but also tumour regression in three of five colorectal and two of two lung cancers. "
11/01/2002 - "Preclinical studies with E7070 showed activity in multiple tumor types, most prominently in colon and lung cancer. "
|1.||N- (3- chloro- 7- indolyl)- 1,4- benzenedisulphonamide (E7070)
|6.||Interleukin 1 Receptor Antagonist Protein (Anakinra)
|8.||Protein Isoforms (Isoforms)
|1.||Heterologous Transplantation (Xenotransplantation)